BUDAPEST, Hungary, April 10, 2024 /PRNewswire/ -- Cariprazine, an original antipsychotic drug developed by Hungarian pharmaceutical company Gedeon Richter Plc. is available in 64 countries and has become a multiple blockbuster in the US, with sales of nearly $3 billion. It is a unique achievement that a Hungarian drug candidate – discovered and developed locally – has been granted FDA and EU approvals, and the company already has several further molecules in its pipeline.
Gedeon Richter Selects Trial Interactive for Clinical Trial Management
Gedeon`s Ryeqo (Relugolix) Receives Approval in Europe
Around 4,500 people in the UK will be eligible for a new oral treatment for uterine fibroids. It follows the National Institute for Health and Care Excellence (NICE) recommendation of relugolix with estradiol and norethisterone acetate, also known as Ryeqo.
AbbVie and Gedeon Richter Plc. have entered a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases.
London, United Kingdom, Wednesday 03 November 2021 – Gedeon Richter UK Ltd. (“Gedeon Richter”) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a UK licence for Benilexa® One Handed (levonorgestrel IUS), as a type of contraception and for the treatment of heavy menstrual bleeding in women of fertile age. This means that healthcare professionals and eligible women now have access to a reloadable, single-handed IUS for the first time on the NHS in the UK. The list price of levonorgestrel IUS is £71.
Gedeon Richter`s Ryeqo Receives Approval in Europe
EC has cleared Ryeqo for the treatment of moderate to severe symptoms of uterine fibroids
DURHAM, N.C.--(BUSINESS WIRE)--Mycovia Pharmaceuticals, Inc. today announced it has entered into an exclusive license and development and technology transfer agreement with Gedeon Richter Plc., based in Budapest, Hungary, to commercialize and manufacture VT-1161 in Europe, Latin America, Australia, Russia and other CIS countries. VT-1161, an oral antifungal product candidate, is currently in Phase 3 clinical trials for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year.